Evidence map›Paper›PMID 42891106›Full record

ArticleChina CDC weekly2026

Smoking-Attributable Mortality in China - Epidemic Stage as a Temporal Dimension in Interpreting GBD Estimates.

Gonghuan Yang, Xia Wan

Abstract read
In one paragraph

Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gonghuan YangInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China.
Xia WanInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco use remains a leading cause of preventable mortality worldwide. Estimates from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) are widely used to quantify smoking-attributable mortality. Over recent GBD cycles, substantial methodological refinements - including improved quantification of cumulative smoking exposure and updated relative risk estimation using the Burden of Proof (BOP) Framework - have strengthened the methodological robustness of smoking-attributable mortality estimates. Nevertheless, recent GBD estimates for China remain difficult to reconcile with evidence from large national cohort studies and repeated surveys. Smoking-attributable mortality is fundamentally shaped by cumulative exposure and long latency, while the stage of the tobacco epidemic reflects the evolution of smoking exposure across successive birth cohorts and calendar periods. Evidence from China suggests that smoking-attributable mortality has not yet reached its expected plateau, whereas GBD estimates imply that smoking has accounted for approximately 30% of male deaths since around 2000. These contrasting patterns reflect different implied temporal trajectories of the tobacco epidemic, rather than simple differences in numerical estimates. We propose that the epidemic stage should be considered an essential temporal dimension when interpreting smoking-attributable mortality estimates. Incorporating the epidemic stage alongside existing modeling approaches would better reflect the differences in the timing of cumulative exposure and evolution of smoking-attributable mortality, thereby improving the interpretation, comparability, and policy relevance of model-based estimates across populations.

Indexed as

Disease Burden StudyTobacco Control

Identifiers

PMID42891106
PMCPMC13673278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.